Chemotherapy-induced Nausea And Vomiting (CINV) Treatment Market
By Drug Type;
5-HT3 Inhibitors, NK1 Inhibitors, and OthersBy Type of Treatment;
Pharmacological Treatment , Non-Pharmacological Treatment, and Prophylactic TreatmentBy Administration Route;
Oral, Intravenous, and SubcutaneousBy Patient Type;
Adult Patients, Pediatric Patients, and Geriatric PatientsBy End-User;
Hospitals, Specialty Clinics, and OthersBy Geography;
North America, Europe, Asia Pacific, Middle East & Africa, and Latin America - Report Timeline (2021 - 2031)Introduction
Global CINV Treatment Market (USD Million), 2021 - 2031
In the year 2024, the Global CINV Treatment Market was valued at USD 2224.36 million. The size of this market is expected to increase to USD 3344.61 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 6.0%.
Chemotherapy-induced Nausea And Vomiting (CINV) Treatment Market
*Market size in USD million
CAGR 6.0 %
Study Period | 2025 - 2031 |
---|---|
Base Year | 2024 |
CAGR (%) | 6.0 % |
Market Size (2024) | USD 2224.36 Million |
Market Size (2031) | USD 3344.61 Million |
Market Concentration | Medium |
Report Pages | 347 |
Major Players
- Merck & Co. Inc
- GlaxoSmithKline plc
- Heron Therapeutics, Inc
- Helsinn Holding S.A.
- Novartis AG
- Baxter Healthcare
- Orchid Healthcare
- Mylan Pharmaceuticals, Inc
- Sun Pharmaceutical Industries Ltd
- Teva Pharmaceutical Industries Ltd
Market Concentration
Consolidated - Market dominated by 1 - 5 major players
Chemotherapy-induced Nausea And Vomiting (CINV) Treatment Market
Fragmented - Highly competitive market without dominant players
Chemotherapy-induced nausea and vomiting (CINV) is a common and distressing side effect experienced by cancer patients undergoing chemotherapy treatment. It significantly impacts patients' quality of life and can lead to treatment interruptions or discontinuations, thereby affecting the effectiveness of cancer therapy. As a result, there has been a growing focus on developing effective treatments to manage CINV and improve patients' overall well-being during cancer treatment.
The global CINV treatment market encompasses a wide range of pharmaceuticals and supportive care therapies aimed at preventing or alleviating chemotherapy-induced nausea and vomiting. This market is driven by several factors, including the increasing incidence of cancer worldwide, advancements in cancer treatments leading to higher survival rates, and the growing recognition of the importance of supportive care in cancer management.
Key players in the CINV treatment market include pharmaceutical companies developing antiemetic drugs specifically designed to target CINV symptoms. These drugs may include serotonin receptor antagonists, neurokinin-1 receptor antagonists, corticosteroids, and other medications that work through different mechanisms to prevent or reduce nausea and vomiting in cancer patients. Additionally, the market for non-pharmacological interventions such as acupuncture, acupressure, and behavioral therapies aimed at managing CINV is also gaining traction. These complementary approaches offer patients alternative methods to alleviate symptoms and improve their overall treatment experience.
The global CINV treatment market is characterized by ongoing research and development efforts aimed at introducing novel therapies with improved efficacy and safety profiles. Furthermore, the market is witnessing increasing collaborations between pharmaceutical companies, academic institutions, and research organizations to accelerate the development of innovative CINV treatments.
In terms of geographical distribution, the market is broadly segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. North America currently dominates the market due to high healthcare expenditure, a well-established healthcare infrastructure, and a significant patient population undergoing cancer treatment. However, the Asia Pacific region is expected to witness rapid growth in the coming years due to increasing cancer incidence rates and improving access to healthcare services.
Global CINV Treatment Market Recent Developments
-
In October 2020, Tetra Bio-Pharma has unveiled its commercial vision on a Robust chemotherapy induced nausea & vomiting portfolio. Company has the strategy to bring the innovative therapies to patients suffering from chemotherapy-induced nausea & vomiting.
-
In July 2019, Nuformix, the pharmaceutical development company used cocrystal technology and commenced the clinical studies for NXP001.
CINV Treatment Market Segment Analysis
In this report, the CINV Treatment Market has been segmented by Drug Type, Type of Treatment, Administration Route, Patient Type, End-User and Geography.
CINV Treatment Market, Segmentation by Drug Type
The CINV Treatment Market has been segmented by Drug Type into 5-HT3 inhibitors, NK1 inhibitors and Others.
5-HT3 inhibitors
5-HT3 inhibitors dominate the CINV Treatment Market, comprising nearly 55% of the drug type segment. These drugs are widely preferred due to their effective control of nausea and vomiting caused by chemotherapy, significantly improving patient comfort during treatment.
NK1 inhibitors
NK1 inhibitors account for about 30% of the market, known for their potent action against delayed CINV. These inhibitors are often combined with other therapies to provide a comprehensive antiemetic regimen enhancing overall treatment efficacy.
Others
The Others category, representing around 15%, includes various supportive drugs that complement primary treatments. This segment encompasses adjunct therapies that target symptom relief and improved quality of life for patients undergoing chemotherapy.
CINV Treatment Market, Segmentation by Type of Treatment
The CINV Treatment Market has been segmented by Type of Treatment into Pharmacological Treatment , Non-Pharmacological Treatment and Prophylactic Treatment.
Pharmacological Treatment
Pharmacological treatment dominates the CINV Treatment Market, accounting for nearly 65% of the segment. This approach includes antiemetic drugs that effectively manage nausea and vomiting associated with chemotherapy, ensuring improved patient compliance and quality of life.
Non-Pharmacological Treatment
Non-pharmacological treatment holds around 20% of the market share and involves methods such as acupuncture, psychological therapy and behavioral interventions. These treatments complement drug therapies by providing holistic care and reducing side effects.
Prophylactic Treatment
Prophylactic treatment accounts for approximately 15% of the market and focuses on preventative strategies to reduce the incidence of chemotherapy-induced nausea and vomiting. This segment emphasizes early intervention protocols to enhance treatment outcomes and patient comfort.
CINV Treatment Market, Segmentation by Administration Route
The CINV Treatment Market has been segmented by Administration Route into Oral, Intravenous and Subcutaneous.
Oral
The oral administration route dominates the CINV Treatment Market with around 55% share. It offers ease of use, patient convenience and a non-invasive approach, making it highly preferred for outpatient and home-based care.
Intravenous
Intravenous administration accounts for approximately 35% of the market, delivering rapid drug absorption and high bioavailability. It is widely used in hospital settings where precise dosing and immediate effects are essential.
Subcutaneous
The subcutaneous route represents around 10% of the segment, known for its minimal invasiveness, steady absorption and ease of administration. It suits patients needing long-term maintenance therapy for CINV.
CINV Treatment Market, Segmentation by Patient Type
The CINV Treatment Market has been segmented by Patient Type into Adult Patients, Pediatric Patients and Geriatric Patients.
Adult Patients
The adult patient segment holds the largest share of approximately 65% in the CINV Treatment Market. This group benefits from effective nausea control, minimal side effects and therapies aimed at enhancing quality of life during chemotherapy.
Pediatric Patients
Making up about 20% of the market, pediatric patients require safe dosing, age-appropriate drug formulations and reduced toxicity to effectively manage chemotherapy-induced nausea and vomiting.
Geriatric Patients
The geriatric patient segment accounts for nearly 15%, needing specialized care due to comorbidities. This includes careful drug selection, dose adjustments and continuous monitoring to prevent adverse effects while managing CINV symptoms.
CINV Treatment Market, Segmentation by End-User
The CINV Treatment Market has been segmented by End-User into Hospitals, Specialty Clinics and Others.
Hospitals
Hospitals dominate the CINV Treatment Market with nearly 60% share. Their advanced healthcare infrastructure and specialized oncology departments support comprehensive chemotherapy care and effective antiemetic treatment administration.
Specialty Clinics
Accounting for about 30% of the market, specialty clinics focus on targeted cancer therapies and personalized patient care, utilizing innovative CINV treatment protocols to enhance patient comfort and outcomes.
Others
The Others segment, representing roughly 10%, includes outpatient centers, home care services and alternative treatment providers, driven by increasing patient preference for convenient access and home-based supportive care.
CINV Treatment Market, Segmentation by Geography
In this report, the CINV Treatment Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East & Africa and Latin America.
Regions and Countries Analyzed in this Report
CINV Treatment Market Share (%), by Geographical Region
North America
North America dominates the CINV Treatment Market with approximately 40% share. The region boasts advanced healthcare infrastructure, strong pharmaceutical presence and widespread adoption of innovative antiemetic therapies.
Europe
Europe holds around 25% of the market, supported by established healthcare systems, increasing oncology research investments and growing awareness of CINV management.
Asia Pacific
The Asia Pacific region is growing rapidly with nearly 20% market share, driven by a rising cancer patient population, improved healthcare facilities and enhanced access to modern CINV treatments.
Middle East & Africa
Middle East & Africa accounts for about 8% of the market, fueled by emerging healthcare infrastructure, increasing government cancer care initiatives and heightened patient awareness.
Latin America
Latin America holds close to 7% market share, supported by growing chemotherapy adoption, expanding patient base and improved access to antiemetic medications.
Market Trends
This report provides an in depth analysis of various factors that impact the dynamics of Global CINV Treatment Market. These factors include; Market Drivers, Restraints and Opportunities Analysis.
Drivers, Restraints and Opportunity Analysis
Drivers
- Increasing Cancer Incidence
- Focus on Supportive Care
-
Government Initiatives and Funding- As a result, they allocate substantial funding towards cancer research, supportive care programs, and public health initiatives aimed at improving patient outcomes and quality of life. These initiatives encompass a spectrum of activities, including grants for academic research institutions, collaborative partnerships between government agencies and pharmaceutical companies, and public awareness campaigns to educate healthcare professionals and patients about CINV management strategies. Additionally, government-sponsored reimbursement schemes and healthcare policies often prioritize access to innovative CINV treatments, ensuring that patients can afford and benefit from the latest therapeutic advancements.
By fostering a conducive environment for research and innovation, governments empower stakeholders in the CINV treatment ecosystem to develop novel therapies, enhance treatment protocols, and expand patient access to supportive care services. Moreover, government-funded clinical trials and registries facilitate the generation of real-world evidence, driving evidence-based decision-making and continuous improvement in CINV treatment outcomes. Overall, government initiatives and funding serve as catalysts for progress in the CINV treatment landscape, promoting collaboration, innovation, and equitable access to high-quality care for cancer patients worldwide.
Restraints
- Adverse Effects of Current Therapies
- Limited Reimbursement Policies
-
High Development Costs- The process of bringing a new CINV treatment from discovery to market approval is lengthy, complex, and capital-intensive, requiring substantial investments in research and development (R&D). Pharmaceutical companies must allocate considerable resources to conduct preclinical studies, clinical trials, regulatory submissions, and post-marketing surveillance to ensure the safety, efficacy, and compliance of their CINV therapies. Additionally, the stringent regulatory requirements imposed by regulatory authorities such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) necessitate comprehensive data generation and validation, further escalating development costs.
The unpredictable nature of clinical trials, including patient recruitment challenges, protocol deviations, and unexpected adverse events, can lead to delays and increased expenditures. Furthermore, the competitive landscape of the pharmaceutical industry intensifies cost pressures, as companies strive to differentiate their products through innovation while managing budgetary constraints. Consequently, addressing the challenge of high development costs requires strategic collaborations, streamlined R&D processes, and innovative financing mechanisms to facilitate sustainable investment in CINV treatment development while ensuring affordability and accessibility for patients worldwide. High development costs pose a barrier to entry for smaller biotechnology firms and startups with limited financial resources, potentially hindering innovation and limiting the diversity of CINV treatment options available to patients.
Opportunities
- Expansion into Adjacent Markets
- Novel Drug Delivery Systems:
-
Personalized Medicine- Personalized medicine involves tailoring medical interventions, including pharmacological treatments, to individual patient characteristics such as genetic makeup, biomarker profiles, and treatment response patterns. In the context of CINV treatment, personalized medicine holds promise for optimizing therapeutic outcomes and minimizing adverse effects by identifying patients who are more susceptible to developing severe nausea and vomiting in response to chemotherapy.
By leveraging genomic and molecular profiling techniques, healthcare providers can identify genetic variations associated with CINV susceptibility and treatment response. This enables the development of targeted therapies that address specific pathways involved in CINV, offering improved efficacy and safety profiles compared to traditional antiemetic drugs. Moreover, personalized medicine allows for the customization of treatment regimens based on individual patient factors, including cancer type, chemotherapy regimen, and comorbidities, to optimize symptom management and enhance patients' overall treatment experience. The integration of personalized medicine approaches into the CINV treatment paradigm not only improves patient outcomes but also fosters a shift towards more precise and individualized cancer care.
Competitive Landscape Analysis
Key players in Global CINV Treatment Market include:
- Merck & Co. Inc
- GlaxoSmithKline plc
- Heron Therapeutics, Inc
- Helsinn Holding S.A.
- Novartis AG
- Baxter Healthcare
- Orchid Healthcare
- Mylan Pharmaceuticals, Inc
- Sun Pharmaceutical Industries Ltd
- Teva Pharmaceutical Industries Ltd
In this report, the profile of each market player provides following information:
- Company Overview and Product Portfolio
- Key Developments
- Financial Overview
- Strategies
- Company SWOT Analysis
- Introduction
- Research Objectives and Assumptions
- Research Methodology
- Abbreviations
- Market Definition & Study Scope
- Executive Summary
- Market Snapshot, By Drug Type
- Market Snapshot, By Type of Treatment
- Market Snapshot, By Administration Route
- Market Snapshot, By Patient Type
- Market Snapshot, By End-User
- Market Snapshot, By Region
- CINV Treatment Market Dynamics
- Drivers, Restraints and Opportunities
- Drivers
-
Increasing Cancer Incidence
-
Focus on Supportive Care
-
Government Initiatives and Funding
-
- Restraints
-
Adverse Effects of Current Therapies
-
Limited Reimbursement Policies
-
High Development Costs
-
- Opportunities
-
Expansion into Adjacent Markets
-
Novel Drug Delivery Systems:
-
Personalized Medicine
-
- Drivers
- PEST Analysis
- Political Analysis
- Economic Analysis
- Social Analysis
- Technological Analysis
- Porter's Analysis
- Bargaining Power of Suppliers
- Bargaining Power of Buyers
- Threat of Substitutes
- Threat of New Entrants
- Competitive Rivalry
- Drivers, Restraints and Opportunities
- Market Segmentation
- CINV Treatment Market, By Drug Type, 2021 - 2031 (USD Million)
- 5-HT3 inhibitors
- NK1 inhibitors
- Others
- CINV Treatment Market, By Type of Treatment, 2021 - 2031 (USD Million)
- Pharmacological Treatment
- Non-Pharmacological Treatment
- Prophylactic Treatment
- CINV Treatment Market, By Administration Route, 2021 - 2031 (USD Million)
- Oral
- Intravenous
- Subcutaneous
- CINV Treatment Market, By Patient Type, 2021 - 2031 (USD Million)
- Adult Patients
- Pediatric Patients
- Geriatric Patients
- CINV Treatment Market, By End-User, 2021 - 2031 (USD Million)
- Hospitals
- Specialty Clinics
- Others
- CINV Treatment Market, By Geography, 2021 - 2031 (USD Million)
-
North America
-
United States
-
Canada
-
-
Europe
-
Germany
-
United Kingdom
-
France
-
Italy
-
Spain
-
Nordic
-
Benelux
-
Rest of Europe
-
-
Asia Pacific
-
Japan
-
China
-
India
-
Australia & New Zealand
-
South Korea
-
ASEAN (Association of South East Asian Countries)
-
Rest of Asia Pacific
-
-
Middle East & Africa
-
GCC
-
Israel
-
South Africa
-
Rest of Middle East & Africa
-
-
Latin America
-
Brazil
-
Mexico
-
Argentina
-
Rest of Latin America
-
-
- CINV Treatment Market, By Drug Type, 2021 - 2031 (USD Million)
- Competitive Landscape
- Company Profiles
-
Merck & Co. Inc
-
GlaxoSmithKline plc
-
Heron Therapeutics, Inc
-
Helsinn Holding S.A.
-
Novartis AG
-
Baxter Healthcare
-
Orchid Healthcare
-
Mylan Pharmaceuticals, Inc
-
Sun Pharmaceutical Industries Ltd
-
Teva Pharmaceutical Industries Ltd
-
- Company Profiles
- Analyst Views
- Future Outlook of the Market